Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials
Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experienced patients with virologic rebound in the phase...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2010-03, Vol.24 (6), p.921-924 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 924 |
|---|---|
| container_issue | 6 |
| container_start_page | 921 |
| container_title | AIDS (London) |
| container_volume | 24 |
| creator | PEETERS, Monika VINGERHOETS, Johan TAMBUYZER, Lotke AZIJN, Hilde HILL, Andrew DE MEYER, Sandra PICCHIO, Gaston |
| description | Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experienced patients with virologic rebound in the phase III DUET trials. Of those experiencing rebound, fewer etravirine-treated than placebo-treated patients developed mutations associated with resistance to protease inhibitors in general and to darunavir in particular, and more patients in the etravirine than the placebo-group maintained baseline darunavir susceptibility at endpoint. |
| doi_str_mv | 10.1097/QAD.0b013e328336ac2a |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_746128325</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746128325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-d08eaee6f34dc9b636e2cfc86ee729b90c17ad354e7fc34427539afbd095b5203</originalsourceid><addsrcrecordid>eNqFkUtLHUEQhZtgiFeTfxBCb8TVmO6ufswsRa8mIISAroeanprYYR7a3SME_PFp9SYBN1nVor5zqjiHsY9SnEjRuM_fT89PRCckEKgawKJX-IZtpHZQGePkHtsIZZuqASf22UFKP4UQRtT1O7avhLTCAmzY4zZHfAgxzMTHMIWceL4lThPFHzR74svAe4zr_ARxnHu-lH3kd3HJhIl4mG9DF_ISeaQUUsYiqjClxQfM1PNpzZjDMqdCPluf32yveY4Bx_SevR3KoA-7echuLrbXZ1-qq2-XX89Oryqvpc5VL2pCIjuA7n3TWbCk_OBrS-RU0zXCS4c9GE1u8KC1cgYaHLpeNKYzSsAhO37xLV_fr5RyO4XkaRxxpmVNrdNWlgyV-T8J4KR1EgqpX0gfl5QiDe1dDBPGX60U7VNBbSmofV1QkX3aHVi7ifq_oj-NFOBoB2DyOA6xBBrSP06ZWlqr4TdbYpyO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733716713</pqid></control><display><type>article</type><title>Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>PEETERS, Monika ; VINGERHOETS, Johan ; TAMBUYZER, Lotke ; AZIJN, Hilde ; HILL, Andrew ; DE MEYER, Sandra ; PICCHIO, Gaston</creator><creatorcontrib>PEETERS, Monika ; VINGERHOETS, Johan ; TAMBUYZER, Lotke ; AZIJN, Hilde ; HILL, Andrew ; DE MEYER, Sandra ; PICCHIO, Gaston</creatorcontrib><description>Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experienced patients with virologic rebound in the phase III DUET trials. Of those experiencing rebound, fewer etravirine-treated than placebo-treated patients developed mutations associated with resistance to protease inhibitors in general and to darunavir in particular, and more patients in the etravirine than the placebo-group maintained baseline darunavir susceptibility at endpoint.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0b013e328336ac2a</identifier><identifier>PMID: 20160633</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral Therapy, Highly Active ; Antiviral agents ; Biological and medical sciences ; Clinical trials ; Drug Resistance, Multiple, Viral - drug effects ; Drug Resistance, Multiple, Viral - genetics ; HIV Infections - drug therapy ; HIV Infections - genetics ; HIV-1 - drug effects ; HIV-1 - genetics ; Human viral diseases ; Humans ; Infectious diseases ; Medical sciences ; Mutation ; non-nucleoside reverse transcriptase inhibitors ; Pharmacology. Drug treatments ; Proteinase inhibitors ; Pyridazines - pharmacology ; Reverse Transcriptase Inhibitors - pharmacology ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>AIDS (London), 2010-03, Vol.24 (6), p.921-924</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-d08eaee6f34dc9b636e2cfc86ee729b90c17ad354e7fc34427539afbd095b5203</citedby><cites>FETCH-LOGICAL-c414t-d08eaee6f34dc9b636e2cfc86ee729b90c17ad354e7fc34427539afbd095b5203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22581664$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20160633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PEETERS, Monika</creatorcontrib><creatorcontrib>VINGERHOETS, Johan</creatorcontrib><creatorcontrib>TAMBUYZER, Lotke</creatorcontrib><creatorcontrib>AZIJN, Hilde</creatorcontrib><creatorcontrib>HILL, Andrew</creatorcontrib><creatorcontrib>DE MEYER, Sandra</creatorcontrib><creatorcontrib>PICCHIO, Gaston</creatorcontrib><title>Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experienced patients with virologic rebound in the phase III DUET trials. Of those experiencing rebound, fewer etravirine-treated than placebo-treated patients developed mutations associated with resistance to protease inhibitors in general and to darunavir in particular, and more patients in the etravirine than the placebo-group maintained baseline darunavir susceptibility at endpoint.</description><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Drug Resistance, Multiple, Viral - drug effects</subject><subject>Drug Resistance, Multiple, Viral - genetics</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - genetics</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - genetics</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>non-nucleoside reverse transcriptase inhibitors</subject><subject>Pharmacology. Drug treatments</subject><subject>Proteinase inhibitors</subject><subject>Pyridazines - pharmacology</subject><subject>Reverse Transcriptase Inhibitors - pharmacology</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtLHUEQhZtgiFeTfxBCb8TVmO6ufswsRa8mIISAroeanprYYR7a3SME_PFp9SYBN1nVor5zqjiHsY9SnEjRuM_fT89PRCckEKgawKJX-IZtpHZQGePkHtsIZZuqASf22UFKP4UQRtT1O7avhLTCAmzY4zZHfAgxzMTHMIWceL4lThPFHzR74svAe4zr_ARxnHu-lH3kd3HJhIl4mG9DF_ISeaQUUsYiqjClxQfM1PNpzZjDMqdCPluf32yveY4Bx_SevR3KoA-7echuLrbXZ1-qq2-XX89Oryqvpc5VL2pCIjuA7n3TWbCk_OBrS-RU0zXCS4c9GE1u8KC1cgYaHLpeNKYzSsAhO37xLV_fr5RyO4XkaRxxpmVNrdNWlgyV-T8J4KR1EgqpX0gfl5QiDe1dDBPGX60U7VNBbSmofV1QkX3aHVi7ifq_oj-NFOBoB2DyOA6xBBrSP06ZWlqr4TdbYpyO</recordid><startdate>20100327</startdate><enddate>20100327</enddate><creator>PEETERS, Monika</creator><creator>VINGERHOETS, Johan</creator><creator>TAMBUYZER, Lotke</creator><creator>AZIJN, Hilde</creator><creator>HILL, Andrew</creator><creator>DE MEYER, Sandra</creator><creator>PICCHIO, Gaston</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>20100327</creationdate><title>Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials</title><author>PEETERS, Monika ; VINGERHOETS, Johan ; TAMBUYZER, Lotke ; AZIJN, Hilde ; HILL, Andrew ; DE MEYER, Sandra ; PICCHIO, Gaston</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-d08eaee6f34dc9b636e2cfc86ee729b90c17ad354e7fc34427539afbd095b5203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Drug Resistance, Multiple, Viral - drug effects</topic><topic>Drug Resistance, Multiple, Viral - genetics</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - genetics</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - genetics</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>non-nucleoside reverse transcriptase inhibitors</topic><topic>Pharmacology. Drug treatments</topic><topic>Proteinase inhibitors</topic><topic>Pyridazines - pharmacology</topic><topic>Reverse Transcriptase Inhibitors - pharmacology</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PEETERS, Monika</creatorcontrib><creatorcontrib>VINGERHOETS, Johan</creatorcontrib><creatorcontrib>TAMBUYZER, Lotke</creatorcontrib><creatorcontrib>AZIJN, Hilde</creatorcontrib><creatorcontrib>HILL, Andrew</creatorcontrib><creatorcontrib>DE MEYER, Sandra</creatorcontrib><creatorcontrib>PICCHIO, Gaston</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PEETERS, Monika</au><au>VINGERHOETS, Johan</au><au>TAMBUYZER, Lotke</au><au>AZIJN, Hilde</au><au>HILL, Andrew</au><au>DE MEYER, Sandra</au><au>PICCHIO, Gaston</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2010-03-27</date><risdate>2010</risdate><volume>24</volume><issue>6</issue><spage>921</spage><epage>924</epage><pages>921-924</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experienced patients with virologic rebound in the phase III DUET trials. Of those experiencing rebound, fewer etravirine-treated than placebo-treated patients developed mutations associated with resistance to protease inhibitors in general and to darunavir in particular, and more patients in the etravirine than the placebo-group maintained baseline darunavir susceptibility at endpoint.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>20160633</pmid><doi>10.1097/QAD.0b013e328336ac2a</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2010-03, Vol.24 (6), p.921-924 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746128325 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | AIDS/HIV Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active Antiviral agents Biological and medical sciences Clinical trials Drug Resistance, Multiple, Viral - drug effects Drug Resistance, Multiple, Viral - genetics HIV Infections - drug therapy HIV Infections - genetics HIV-1 - drug effects HIV-1 - genetics Human viral diseases Humans Infectious diseases Medical sciences Mutation non-nucleoside reverse transcriptase inhibitors Pharmacology. Drug treatments Proteinase inhibitors Pyridazines - pharmacology Reverse Transcriptase Inhibitors - pharmacology Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| title | Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T01%3A00%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Etravirine%20limits%20the%20emergence%20of%20darunavir%20and%20other%20protease%20inhibitor%20resistance-associated%20mutations%20in%20the%20DUET%20trials&rft.jtitle=AIDS%20(London)&rft.au=PEETERS,%20Monika&rft.date=2010-03-27&rft.volume=24&rft.issue=6&rft.spage=921&rft.epage=924&rft.pages=921-924&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0b013e328336ac2a&rft_dat=%3Cproquest_cross%3E746128325%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733716713&rft_id=info:pmid/20160633&rfr_iscdi=true |